Thanks Peter, glad you liked... You know, I consider that the reported arguments from the shorts regarding CLTR (from Avalon in particular) have been about 20% worthy of consideration, and about 80% pure slam-job or scare-job. I personally don't have access to and haven't read the actual research reports from these outfits, so I've tried on occasion to be careful to refer to and criticize their reported arguments - quite possible that their actual arguments are more sophisticated than what we've seen and are being garbled by reporters (wouldn't be the first time we've seen that!).
Assuming the reported arguments are roughly accurate, I think that Avalon et al should be careful here not to overplay their hand, or I think they may end up without much respect among serious followers of biotech once this story has played out (we may continue to have respect for their PR-attack abilities, as we might respect the abilities of a Dick Morris or James Carville as political attack-dogs, but perhaps less so for their biotech insights...). It's been an easy bet so far to figure that Coulter is doing something very new and difficult, and likely to experience disappointing delays and bumps in the road. But when I see these guys mention this situation in the same breath with SNRS, I think they're pretty far off-base.
An interesting piece you found on SAFS! Hmmm, cleaning and lawn and garden products, cancer treatments, Internet tie-ins, management predisposed toward dilution and making its study investigators uncomfortable with hyping of results - where is Avalon when you need them? <g> Who knows, perhaps their GBC-590 will turn out to be a good treatment, but I remember thinking (after a very cursory investigation) when I first ran across this outfit not too long ago (saw the GBC-590 press release, I think) that this looked like a questionable outfit. Don't know if I would have the kahoonas to short it at this point, given the small float/limited liquidity...
Gordon |
